Bloomberg quotes the Commissioner of the FDA Marty Makary as having said that the agency is “taking a hard look” at whether Sarepta’s (SRPT) Elevidys should stay on the market after a third death following dosing with one of Sarepta’s gene therapies was reported.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Needham downgrades Sarepta after patient death, questions management credibility
- Sarepta downgraded to Hold from Buy at Needham
- Sarepta CEO says didn’t disclose patient death on Weds. call, ‘wasn’t salient’
- Another liver toxicity death adds to Sarepta concerns, says Morgan Stanley
- Sarepta price target lowered to $20 from $28 at BofA